 Xenograft Model Antitumor Assays
"Xenograft Model Antitumor Assays" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
| Descriptor ID |
D023041
|
| MeSH Number(s) |
E05.337.550.200.900 E05.624.850
|
| Concept/Terms |
Xenograft Model Antitumor Assays- Xenograft Model Antitumor Assays
- Tumor Xenograft Assay
- Xenograft Antitumor Assays
- Antitumor Assay, Xenograft
- Antitumor Assays, Xenograft
- Assay, Xenograft Antitumor
- Assays, Xenograft Antitumor
- Xenograft Antitumor Assay
- Antitumor Assays, Xenograft Model
|
Below are MeSH descriptors whose meaning is more general than "Xenograft Model Antitumor Assays".
Below are MeSH descriptors whose meaning is more specific than "Xenograft Model Antitumor Assays".
This graph shows the total number of publications written about "Xenograft Model Antitumor Assays" by people in this website by year, and whether "Xenograft Model Antitumor Assays" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 5 | 5 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 2 | 2 | | 2005 | 0 | 5 | 5 | | 2006 | 2 | 4 | 6 | | 2007 | 0 | 5 | 5 | | 2008 | 2 | 9 | 11 | | 2009 | 1 | 14 | 15 | | 2010 | 1 | 12 | 13 | | 2011 | 2 | 13 | 15 | | 2012 | 2 | 23 | 25 | | 2013 | 2 | 19 | 21 | | 2014 | 0 | 19 | 19 | | 2015 | 3 | 26 | 29 | | 2016 | 3 | 20 | 23 | | 2017 | 2 | 35 | 37 | | 2018 | 2 | 27 | 29 | | 2019 | 1 | 27 | 28 | | 2020 | 1 | 29 | 30 | | 2021 | 1 | 13 | 14 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 2 | 2 | | 2024 | 6 | 18 | 24 | | 2025 | 0 | 19 | 19 |
To return to the timeline, click here.
Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.
-
Offenbacher R, Jackson KW, Hayashi M, Zhang J, Peng D, Tan Y, Stewart TM, Ciero P, Foley J, Casero RA, Cahan P, Loeb DM. Polyamine Depletion by D,L-a-Difluoromethylornithine Inhibits Ewing Sarcoma Metastasis by Inducing Ferroptosis. Clin Cancer Res. 2025 Oct 01; 31(19):4196-4210.
-
Rodríguez-Lobato LG, Cardús O, Mañé-Pujol J, Battram AM, Vaqué-Salsench S, Carpio J, Pérez-Amill L, Calderón H, Martín-Antonio B, Oliver-Caldés A, Lozano E, Moreno DF, Ortiz-Maldonado V, Salas MQ, de Daniel A, Tovar N, Cibeira MT, Rosiñol L, Bladé J, Juan M, Urbano-Ispizua Á, Engel P, Fernández de Larrea C. Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited. Cancer Immunol Res. 2025 Sep 02; 13(9):1374-1390.
-
Balakrishnan I, Madhavan K, Pierce A, Michlin J, Brunt B, Lakshmanachetty S, Wang D, DeSisto J, Nuss ZJ, Davidson N, Walker F, Suresh A, Donson A, Sanford B, Jones KL, Danis EP, Mitra SS, Green AL, Dahl N, Vibhakar R, Venkataraman S. Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma. Cancer Res. 2025 Aug 15; 85(16):3089-3110.
-
Feng Y, Haupt B, Huynh TT, Meshaw R, Martin-Regalado A, Thakur A, Duffy JT, Alzeer A, Siegel DA, Barnes A, Simberg D, Zalutsky MR, Balyasnikova IV. Longitudinal Imaging Reveals Tumor Uptake and Prolonged Retention of Bispecific T Cell-Engaging Antibody in GBM via Passive and Active Mechanisms. Clin Cancer Res. 2025 Aug 14; 31(16):3537-3549.
-
Zhou X, Moreira S, Restelli C, Wang H, Jahangiri S, Aryal S, Tsao E, Zhang P, Niu M, Kumar H, Balde Z, Vujovic A, Liu L, Wong N, Arruda A, Minden MD, Zhou Y, Ravi B, Qi J, Li C, Hope KJ, Lu R. Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models. Sci Transl Med. 2025 Aug 06; 17(810):eadn5400.
-
Singh N, Ali M, Biswal P, Jaiswal A, Mishra D, Agarwal R, Zaidi R, Singh RP. Inhibition of Growth and Survival of Head and Neck Cancer Cells by Silibinin Involves the Down-Regulation of Erk1/2, AKT and STAT3 Signaling. Mol Carcinog. 2025 Oct; 64(10):1735-1750.
-
Sun Y, Fujiwara Y, Torphy RJ, Yee EJ, Guo Y, Sun Z, Hu J, Eck E, Terai T, Schulick RD, Zhu Y. CD93 blockade overcomes sunitinib resistance in pancreatic neuroendocrine tumors. Mol Ther. 2025 Oct 01; 33(10):5017-5027.
-
Tiago M, Purwin TJ, Stefanski CD, da Silva RO, Fane ME, Chhabra Y, Haj JI, Teh JL, Kadamb R, Cai W, Rosenbaum SR, Chua V, Hacohen N, Davies MA, Villanueva J, Chervoneva I, Weeraratna AT, Erkes DA, Capparelli C, Aguirre-Ghiso JA, Aplin AE. Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma. J Clin Invest. 2025 Sep 16; 135(18).
-
Oliver-Caldes A, Mañe Pujol J, Battram AM, Perez-Amill L, Bachiller M, Calderon H, Castella M, Carpio J, Salsench SV, Tovar N, Cardus O, Urbano-Ispizua A, Moreno DF, Rodríguez-Lobato LG, Lozano E, Rosiñol L, Juan M, Martín-Antonio B, Fernández de Larrea C. TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse model. Oncoimmunology. 2025 Dec; 14(1):2529632.
-
Chafe SC, Zhai K, Aghaei N, Miletic P, Huang Z, Brown KR, Mobilio D, Young D, Suk Y, Grewal S, McKenna D, Alizada Z, Kieliszek AM, Lam FC, Escudero L, Huang Q, Huebner A, Lu J, Ang P, Anand A, Custers S, Apel E, Slassi S, Brakel B, Kim J, Liu JKC, Bassey-Archibong BI, Abdo R, Shargall Y, Lu JQ, Cutz JC, Zhang Q, Li SS, Venugopal C, Hynds RE, Dufour A, Moffat J, Swanton C, Bao S, Singh SK. A genome-wide in vivo CRISPR activation screen identifies BACE1 as a therapeutic vulnerability of lung cancer brain metastasis. Sci Transl Med. 2025 Jul 02; 17(805):eadu2459.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|